CMS Unveils Major New Outcomes-Based Model for Tech-Enabled Care: What Digital Health Leaders Need to Know
Is this the most meaningful advancement for tech-enabled care delivery since COVID? Many industry experts say yes. Here’s a comprehensive breakdown of what the Centers for Medicare & Medicaid Services (CMS), through the Center for Medicare and Medicaid Innovation (CMMI), announced. Plus, we discuss what it could mean for digital health companies, virtual care providers, remote patient monitoring platforms, and chronic care management organizations.
What CMS announced: a new outcomes-based payment model under Medicare Part B
CMMI released a new payment model designed to accelerate adoption of healthcare technology that improves outcomes for Medicare beneficiaries. Early reactions across the digital health ecosystem suggest this could be the biggest tailwind for tech-enabled care since the surge in virtual care adoption during the COVID-19 pandemic.
At a high level, CMS is introducing a technology-supported chronic care model that combines recurring payments with outcomes-based incentives under Medicare Part B. Participating organizations can receive ongoing payments for managing beneficiaries with certain chronic conditions and additional payments for hitting specific clinical outcome targets.
A few notable aspects:
- Beneficiaries can self-enroll or be referred. Unlike many CMS programs, the model does not require an initiating visit with an existing provider.
- Providers and technology companies can apply beginning January 2026.
- The model officially launches July 1, 2026.
- CMS will evaluate performance and decide whether to expand or permanently adopt the model.
While the announcement is generating excitement, key details have not yet been released. To make sense of what is known and what remains unclear, I spoke with two experts from Manatt Health: Jared Augenstein, Senior Managing Director, and Randi Seigel, Partner and digital health regulatory expert. Their comments below are jointly attributed.

Key questions about CMS’s outcomes-based pricing model
Why is the outcomes-based pricing model such a big innovation?
RS/JA: This model stands out because it is explicitly technology-forward. The structure blends recurring, not-at-risk payments with outcomes-based payments measured at the population level. CMS will define standardized, guideline-informed metrics for each condition.
Examples include:
- Hypertension: blood pressure control
- Diabetes: HbA1c improvement
- Depression: PHQ-9 score changes
Specific outcome targets (for example, points of improvement required) will be released in forthcoming guidance.
When will CMS release the actual payment rates?
RS/JA: We expect to see payment rates in late 2025 or early 2026. CMS is expected to release an RFA very soon, but we do not know whether payment rates will be included.
Which digital health companies are best positioned to participate?
Likely early adopters
RS/JA: Companies offering virtual coaching, remote patient monitoring (RPM), chronic condition management, or integrated clinical services are strong candidates. Those already aligned with Medicare Advantage or commercial outcomes-based models have an advantage, especially if they operate an affiliated physician entity that can enroll in Medicare Part B.
Scaled organizations in CKD, MSK, diabetes, mental health, and metabolic health are expected to be among the earliest adopters.
Companies less likely to participate
RS/JA: Companies lacking an affiliated provider group cannot enroll in Medicare. They would need to partner with or contract through a Medicare-enrolled organization. Companies unable to comply with HIPAA, HIE connectivity requirements, or FDA device rules may also sit this out.
Is this really the biggest tailwind for digital health since COVID?
RS/JA: It is a significant tailwind, especially for organizations already successfully delivering chronic care improvements. However, unlike COVID-era telehealth flexibilities, this model does not open the doors to everyone. Requirements include:
- Eligibility for Medicare enrollment
- Compliance with HIPAA
- Use of FDA-cleared or exempt devices, where required
- Acceptance into the program by CMS
- Ability to take on outcomes-based financial risk
In other words, strong companies may thrive, but many will not qualify.
What hasn’t CMS shared yet?
RS/JA: The two most important unknowns are:
Actual payment rates and the structure of recurring vs. at-risk payments.
Specific measurement targets for clinical outcomes.
These details will ultimately shape whether the model is financially viable for participants.
What role does primary care play?
RS/JA: CMS positions primary care clinicians as central partners, but participation appears optional. PCPs can bill up to $100 per beneficiary per year for reviewing documentation submitted by ACCESS participants, as long as they document this review. Beneficiaries can self-enroll, so CMS will need to clarify how PCPs become aware that a patient joined the program.
Could this model increase fraud risk?
RS/JA: Yes. Participants can request to waive beneficiary cost-sharing entirely. If every participant does so — which seems likely — oversight challenges increase. There is also no cost-sharing for co-managing provider reviews, another potential vulnerability CMS will need to monitor.
Will this increase utilization of digital health tools?
RS/JA: Absolutely. Beneficiaries will gain broader access to tools that historically were self-pay or commercially reimbursed only. We expect utilization to rise significantly, especially in the first few years. CMS will need to clarify how this model interacts with existing RPM, RTM, and primary care management programs.
What does this mean for companies like Virta, Omada, Hinge, and others?
RS/JA: It represents a meaningful opportunity. These companies already have the infrastructure, clinical models, and risk-bearing capabilities to participate in Medicare. They know how to manage outcomes and operate in value-based environments.
What about infrastructure vendors and CMS’s tools directory?
RS/JA: The Tools Directory is one of the most intriguing aspects. CMS is essentially creating a marketplace where vendors can showcase their technology directly to ACCESS participants and even offer discounts or credits, within fraud and abuse guidelines. This could become a powerful marketing channel, though potentially very crowded.
Bottom line
CMS’s new outcomes-based payment model has the potential to reshape tech-enabled chronic care delivery in Medicare. For companies with established clinical models, compliant infrastructure, and the ability to manage outcomes at scale, the ACCESS model may represent one of the most important federal opportunities since the pandemic.
Much more guidance is coming, including payment rates, outcomes targets, and operational details. We will continue tracking every update to help digital health leaders understand what this model means for strategy, investment, and future growth.
These responses can be attributed to both of them. Stay tuned for far more on this new model. I’ll do my best to unpack it for you.
Do you have additional questions? Shoot them over to me and I’ll do my best to get them over to the right folks. I’m also curious for your thoughts on the model if you’re a care delivery provider that potentially could participate. Shoot me a note at christina@secondopinion.media. Jared and Randi have also offered to help, and they can be reached at jaugenstein@manatt.com and rseigel@manatt.com.
Not already a Second Opinion subscriber?
Get weekly insights on health‑tech delivered straight to your inbox. Join the mailing list for free
Or copy & paste this link into your browser:
https://secondopinion.media/subscribe
Upcoming Sessions
Live conversations with the people shaping healthcare.
Verifying AI in Medicine: Is Healthcare AI Actually Ready for Deployment?
Is AI ready for real-world clinical care? Dr. Zak Kohane and Protege’s Engy Ziedan debate what it takes to safely trust AI in diagnosis and treatment, from benchmark performance and clinical evidence to whether we’re holding AI to a higher standard than humans.
Why Are Hospitals Hiring Chief AI Officers?
As AI moves from pilots into day-to-day healthcare operations, health systems are having to decide who should actually own the
Where are AI Agents Actually Working in Healthcare, and Why?
While the healthcare industry remains locked in a high-level debate over the theoretical potential of artificial intelligence, a select group of
Top Employers Share What Healthcare Startups Need to Know in 2026
As enterprise health purchasers face volatile medical cost trends and tightening operational margins, the standard vendor pitch of "improved clinical efficiency&
Peptide Therapy: Where Do We Go From Here?
Watch the full webinar Peptide therapies have moved from niche biohacking circles into mainstream medicine, reshaping conversations around weight management, metabolic health,
Not everyone can access the top 1% of physicians. Will AI change that?
Historically, top-tier medical expertise was limited by wealth and geography. As AI reshapes healthcare delivery, a vital question emerges: can it democratize intelligence to give everyone access to the caliber of care typically reserved for the top 1%?
Privacy AI and the Future of HIPAA
Watch the Full Webinar As AI reshapes healthcare and more patient data flows beyond traditional clinical settings, the rules governing privacy, access,
What will AI do for employer healthcare and benefits?
Employer healthcare may be one of the most practical — and overlooked — proving grounds for AI.
Hospitals as the new go-to-market, lessons from the trenches
Watch the Full Webinar Health systems are entering a new frontier, one where innovation isn’t optional, and meaningful change requires creativity,